Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA

References

• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
   PubMed Web of Science ®Google Scholar
• GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
   PubMed Web of Science ®Google Scholar
• ToyookaSKiuraKMitsudomiTEGFR mutation and response of lung cancer to gefitinibN Engl J Med200535220213615901872
   PubMed Web of Science ®Google Scholar
• JiWChoiCMRhoJKMechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancerBMC Cancer20131360624369725
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• FisherRPusztaiLSwantonCCancer heterogeneity: implications for targeted therapeuticsBr J Cancer2013108347948523299535
   PubMed Web of Science ®Google Scholar
• WeberBMeldgaardPHagerHDetection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assaysBMC Cancer20141429424773774
   PubMed Web of Science ®Google Scholar
• JiangTRenSZhouCRole of circulating-tumor DNA analysis in non-small cell lung cancerLung Cancer201590212813426415994
   PubMed Web of Science ®Google Scholar
• BernabeRHicksonNWallaceABlackhallFHWhat do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?Eur J Cancer201781667328609695
   PubMed Web of Science ®Google Scholar
• FrancisGSteinSCirculating cell-free tumour DNA in the management of cancerInt J Mol Sci2015166141221414226101870
   PubMed Web of Science ®Google Scholar
• LiangZChengYChenYEGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIsCancer Lett201740318619428642172
   PubMed Web of Science ®Google Scholar
• LinCCHuangWLWeiFSuWCWongDTEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerExpert Rev Mol Diagn201515111427144026420338
   PubMed Web of Science ®Google Scholar
• LiRYeSBHeYDetection of epidermal growth factor receptor gene mutations in different types of non-small cell lung cancer by droplet digital PCR and amplification refractory mutation systemZhonghua Bing Li Xue Za Zhi20174611764768 Chinese [with English abstract].29136689
   PubMedGoogle Scholar
• ZhouCWangMChengYDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): circulating tumour (ct) DNA analysis across 3 platformsAnn Oncol201728Suppl 5v460v496
   Google Scholar
• ZhuLZhangSXunYComparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790M mutation detection in non-small cell lung cancer after failure of tyrosine kinase inhibitor treatmentPathol Oncol Res Epub201793
   Web of Science ®Google Scholar
• WangWSongZZhangYA Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceCancer Med20176115416228000387
   PubMed Web of Science ®Google Scholar
• ThressKSBrantRCarrTHEGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291Lung Cancer201590350951526494259
   PubMed Web of Science ®Google Scholar
• KasaharaNKenmotsuHSerizawaMPlasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancerLung Cancer201710613814428285688
   PubMed Web of Science ®Google Scholar
• InukaiMToyookaSItoSPresence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancerCancer Res200666167854785816912157
   PubMed Web of Science ®Google Scholar
• ZhuGYeXDongZHighly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancerJ Mol Diagn201517326527225769900
   PubMed Web of Science ®Google Scholar
• YuQHuangFZhangMMultiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patientsMol Med Rep20171621157116629067441
   PubMed Web of Science ®Google Scholar
• SuzawaKYamamotoHOhashiKOptimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR systemOncol Rep20173753100310628405680
   PubMed Web of Science ®Google Scholar
• ZhengDYeXZhangMZPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistanceSci Rep201662091326867973
   PubMed Web of Science ®Google Scholar
• SacherAGPaweletzCDahlbergSEProspective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancerJAMA Oncol2016281014102227055085
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• WhitingPFRutjesAWWestwoodMEQUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studiesAnn Intern Med2011155852953622007046
   PubMed Web of Science ®Google Scholar
• GlasASLijmerJGPrinsMHBonselGJBossuytPMMThe diagnostic odds ratio: a single indicator of test performanceJ Clin Epidemiol200356111129113514615004
   PubMed Web of Science ®Google Scholar
• van EnstWAOchodoEScholtenRJHooftLLeeflangMMInvestigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological studyBMC Med Res Methodol2014147024884381
   PubMed Web of Science ®Google Scholar
• QiuMWangJXuYCirculating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysisCancer Epidemiol Biomarkers Prev201524120621225339418
   PubMed Web of Science ®Google Scholar
• LuoJShenLZhengDDiagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysisSci Rep20144626925201768
   PubMed Web of Science ®Google Scholar
• MarinisFDChoBCKimDWKimSWHochmairMJMetroGASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC)J Clin Oncol20173515 Suppl90369036
   Google Scholar
• JenkinsSYangJCRamalingamSSPlasma ctDNA Analysis for detection of the EGFR T790M Mutation in patients with advanced non-small cell lung cancerJ Thorac Oncol20171271061107028428148
   PubMed Web of Science ®Google Scholar
• KarlovichCGoldmanJWSunJMAssessment of EGFR Mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)Clin Cancer Res201622102386239526747242
   PubMed Web of Science ®Google Scholar
• GuJZangWLiuBEvaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison studyOncotarget2017840678106782028978074
   PubMedGoogle Scholar
• IshiiHAzumaKSakaiKDigital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samplesOncotarget2015631308503085826334838
   PubMed Web of Science ®Google Scholar
• OxnardGRPaweletzCPKuangYNoninvasive detection of response and resistance in EGFR-Mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNAClin Cancer Res20142061698170524429876
   PubMed Web of Science ®Google Scholar
• MokTSWuYLAhnMJOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med2017376762964027959700
   PubMed Web of Science ®Google Scholar
• SoriaJCOheYVansteenkisteJOsimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancerN Engl J Med2018378211312529151359
   PubMed Web of Science ®Google Scholar
• PopatSOsimertinib as first-line treatment in EGFR-Mutated non-small-cell lung cancerN Engl J Med2018378219219329320658
   PubMed Web of Science ®Google Scholar
• ZhangXChangNYangGA comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasmaOncotarget201786711201411202329340107
   PubMedGoogle Scholar
• WeiZShahNDengCXiaoXZhongTLiXCirculating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSpringer-plus2016553127186495
   PubMedGoogle Scholar
• TakahamaTSakaiKTakedaMDetection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)Oncotarget2016736584925849927542267
   PubMed Web of Science ®Google Scholar
• SekiYFujiwaraYKohnoTPicoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma dna to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitorsOncologist201621215616426768482
   PubMed Web of Science ®Google Scholar
• XuTKangXYouXCross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor dna from non-small cell lung carcinoma patient plasmaTheranostics2017761437144628529628
   PubMed Web of Science ®Google Scholar